Table 1.
Patient characteristics and previous treatments
| Patient characteristics | n (%) |
|---|---|
| Median age (range) | 62.5 (47–78) years |
| Male | 10 (67) |
| Female | 5 (33) |
| Ki-67: 6–19% | 5 (33) |
| Ki-67: 2–5% | 10 (67) |
| Functioning NETs | 4 (27) |
| Non-functioning NETs | 11 (73) |
| Site of origin | |
| Pancreas | 7 (47) |
| Small intestine | 3 (20) |
| Duodenum | 1 (7) |
| Stomach | 1 (7) |
| Rectum | 1 (7) |
| Lung | 1 (7) |
| Unknown | 1 (7) |
| Stage (AJCC 7th edn) | |
| IIIA and B | 1 (7) |
| IV (Liver) | 12 (80) |
| IV (other distant organs) | 2 (13) |
| Treatments before initiation of TeBeSa | |
| Surgery | 6 (40) |
| Debulking | 5 (33) |
| Whipple | 1 (7) |
| Radiolabelled peptides | 2 (13) |
| Chemotherapy | 12 (80) |
| Platinum based | 8 (53) |
| Streptozotocin/5-fluorouracil | 6 (40) |
| Anthracycline | 1 (7) |
| Docetaxel | 1 (7) |
| Other medical therapies | |
| Interferon | 1 (7) |
| Octreotide long-acting release | 100 (15) |
| Everolimus | 7 (1) |
| Lines of medical therapies | |
| 1 | 10 (67) |
| 2 | 4 (28) |
| 3 | 1 (7) |